GSK plc's subsidiary TESARO announced on April 27, 2026, that the Delaware court dismissed a claim against it by AnaptysBio, although the main contract dispute remains unresolved. TESARO maintains that the allegations are without merit and continues to seek a declaratory judgment in the ongoing litigation.